Open AccessGlucagon like Peptide-1(GLP-1) a Novel Therapeutic Strategy in Non-Alcoholic Fatty Liver Disease (NAFLD)
Author(s) -
Ebrahim Abbasi Oshaghi
Publication year - 2017
Publication title -
avicenna journal of medical biochemistry
Language(s) - English
Resource type - Journals
ISSN - 2345-4113
DOI - 10.15171/ajmb.2017.10
Subject(s) - steatohepatitis , fatty liver , type 2 diabetes , glucagon like peptide 1 receptor , medicine , insulin resistance , lipotoxicity , incretin , type 2 diabetes mellitus , glucagon like peptide 1 , nonalcoholic fatty liver disease , endocrinology , diabetes mellitus , agonist , disease , insulin , receptor
Non-alcoholic fatty liver disease (NAFLD) is a main cause of liver disease and its global prevalence is estimated to be 24%. At present no approved medicines are available for NAFLD treatment. Glucagon-like peptide-1 (GLP-1) is a significant regulator of energy balance, show potential efficacy in the management of NAFLD. GLP-1 and GLP-1 receptor agonist (GLP-1RAs) are attractive options for the treatment of type 2 diabetes (T2D) since they efficiently reduce weight, HbA1C and blood glucose without having a risk of hypoglycaemia. This incretin hormone by normalizing of insulin resistance (IR), oxidative stress, lipid accumulation, lipotoxicity, and liver cell apoptosis is proposed for the management of NAFLD and nonalcoholic steatohepatitis (NASH) patient. Hence, the aim of this review was to discuss the useful effects of GLP-1, GLP-1 receptor agonist (GLP-1RAs) and dipeptidyl peptidase-4 (DPP-4) on NAFLD. In this paper we provided a new finding which highlighted the role of GLP-1 and GLP-1RAs in the treatment of NAFLD.